18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Programming multicellular assembly with synthetic cell adhesion molecules

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cell adhesion molecules are ubiquitous in multicellular organisms, specifying precise cell–cell interactions in processes as diverse as tissue development, immune cell trafficking and the wiring of the nervous system 14 . Here we show that a wide array of synthetic cell adhesion molecules can be generated by combining orthogonal extracellular interactions with intracellular domains from native adhesion molecules, such as cadherins and integrins. The resulting molecules yield customized cell–cell interactions with adhesion properties that are similar to native interactions. The identity of the intracellular domain of the synthetic cell adhesion molecules specifies interface morphology and mechanics, whereas diverse homotypic or heterotypic extracellular interaction domains independently specify the connectivity between cells. This toolkit of orthogonal adhesion molecules enables the rationally programmed assembly of multicellular architectures, as well as systematic remodelling of native tissues. The modularity of synthetic cell adhesion molecules provides fundamental insights into how distinct classes of cell–cell interfaces may have evolved. Overall, these tools offer powerful abilities for cell and tissue engineering and for systematically studying multicellular organization.

          Abstract

          Synthetic cell adhesion molecules yield customized cell–cell interactions with adhesion properties that are similar to native interactions, and offer abilities for cell and tissue engineering and for systematically studying multicellular organization.

          Related collections

          Most cited references63

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          UniProt: the universal protein knowledgebase in 2021

          (2020)
          Abstract The aim of the UniProt Knowledgebase is to provide users with a comprehensive, high-quality and freely accessible set of protein sequences annotated with functional information. In this article, we describe significant updates that we have made over the last two years to the resource. The number of sequences in UniProtKB has risen to approximately 190 million, despite continued work to reduce sequence redundancy at the proteome level. We have adopted new methods of assessing proteome completeness and quality. We continue to extract detailed annotations from the literature to add to reviewed entries and supplement these in unreviewed entries with annotations provided by automated systems such as the newly implemented Association-Rule-Based Annotator (ARBA). We have developed a credit-based publication submission interface to allow the community to contribute publications and annotations to UniProt entries. We describe how UniProtKB responded to the COVID-19 pandemic through expert curation of relevant entries that were rapidly made available to the research community through a dedicated portal. UniProt resources are available under a CC-BY (4.0) license via the web at https://www.uniprot.org/.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

            Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL). Two children with relapsed and refractory pre-B-cell ALL received infusions of T cells transduced with anti-CD19 antibody and a T-cell signaling molecule (CTL019 chimeric antigen receptor T cells), at a dose of 1.4×10(6) to 1.2×10(7) CTL019 cells per kilogram of body weight. In both patients, CTL019 T cells expanded to a level that was more than 1000 times as high as the initial engraftment level, and the cells were identified in bone marrow. In addition, the chimeric antigen receptor T cells were observed in the cerebrospinal fluid (CSF), where they persisted at high levels for at least 6 months. Eight grade 3 or 4 adverse events were noted. The cytokine-release syndrome and B-cell aplasia developed in both patients. In one child, the cytokine-release syndrome was severe; cytokine blockade with etanercept and tocilizumab was effective in reversing the syndrome and did not prevent expansion of chimeric antigen receptor T cells or reduce antileukemic efficacy. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment. The other patient had a relapse, with blast cells that no longer expressed CD19, approximately 2 months after treatment. Chimeric antigen receptor-modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Getting to the site of inflammation: the leukocyte adhesion cascade updated.

              Neutrophil recruitment, lymphocyte recirculation and monocyte trafficking all require adhesion and transmigration through blood-vessel walls. The traditional three steps of rolling, activation and firm adhesion have recently been augmented and refined. Slow rolling, adhesion strengthening, intraluminal crawling and paracellular and transcellular migration are now recognized as separate, additional steps. In neutrophils, a second activation pathway has been discovered that does not require signalling through G-protein-coupled receptors and the signalling steps leading to integrin activation are beginning to emerge. This Review focuses on new aspects of one of the central paradigms of inflammation and immunity--the leukocyte adhesion cascade.
                Bookmark

                Author and article information

                Contributors
                wendell.lim@ucsf.edu
                Journal
                Nature
                Nature
                Nature
                Nature Publishing Group UK (London )
                0028-0836
                1476-4687
                12 December 2022
                12 December 2022
                2023
                : 614
                : 7946
                : 144-152
                Affiliations
                [1 ]GRID grid.266102.1, ISNI 0000 0001 2297 6811, UCSF Cell Design Institute, , University of California, ; San Francisco, CA USA
                [2 ]GRID grid.266102.1, ISNI 0000 0001 2297 6811, Department of Cellular and Molecular Pharmacology, , University of California, ; San Francisco, CA USA
                [3 ]GRID grid.266102.1, ISNI 0000 0001 2297 6811, Center for Cellular Construction, , University of California, ; San Francisco, CA USA
                [4 ]GRID grid.47840.3f, ISNI 0000 0001 2181 7878, Department of Bioengineering, , University of California, ; Berkeley, CA USA
                [5 ]GRID grid.266102.1, ISNI 0000 0001 2297 6811, Department of Neurology, Weill Institute for Neuroscience, , University of California, ; San Francisco, CA USA
                [6 ]GRID grid.266102.1, ISNI 0000 0001 2297 6811, Program in Craniofacial Biology, , University of California, ; San Francisco, CA USA
                [7 ]GRID grid.266102.1, ISNI 0000 0001 2297 6811, Department of Orofacial Sciences, , University of California, ; San Francisco, CA USA
                [8 ]GRID grid.266102.1, ISNI 0000 0001 2297 6811, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, , University of California, ; San Francisco, CA USA
                [9 ]GRID grid.50956.3f, ISNI 0000 0001 2152 9905, Department of Pediatrics, , Cedars-Sinai Medical Center, ; Los Angeles, CA USA
                [10 ]GRID grid.499295.a, ISNI 0000 0004 9234 0175, Chan Zuckerberg Biohub, ; San Francisco, CA USA
                [11 ]GRID grid.34428.39, ISNI 0000 0004 1936 893X, Present Address: Department of Mechanical and Aerospace Engineering, , Carleton University, ; Ottawa, Ontario Canada
                [12 ]GRID grid.511646.1, ISNI 0000 0004 7480 276X, Present Address: Maze Therapeutics, ; San Francisco, CA USA
                Author information
                http://orcid.org/0000-0003-0735-8729
                http://orcid.org/0000-0002-8028-0772
                http://orcid.org/0000-0003-3814-861X
                http://orcid.org/0000-0002-9473-8596
                http://orcid.org/0000-0002-6254-7082
                http://orcid.org/0000-0002-1890-5364
                http://orcid.org/0000-0003-4052-8056
                Article
                5622
                10.1038/s41586-022-05622-z
                9892004
                36509107
                b69dcfbe-a2f3-4994-8025-19950b11be40
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 28 October 2021
                : 2 December 2022
                Categories
                Article
                Custom metadata
                © The Author(s), under exclusive licence to Springer Nature Limited 2023

                Uncategorized
                synthetic biology,cadherins,protein engineering,integrins,tissue engineering
                Uncategorized
                synthetic biology, cadherins, protein engineering, integrins, tissue engineering

                Comments

                Comment on this article